Amgen scored a second approval for Prolia (denosumab) for the treatment of osteoporosis just days after its first. Last week, Prolia was approved in the European Union. Now, Prolia has received approval from the FDA.
Meanwhile, Amgen is ramping up promotion efforts in anticipation of a launch. The company is hiring and deploying nearly 1,000 additional sales reps to detail the drug.
